Ambys Medicines Revenue and Competitors

Location

$187M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Ambys Medicines's estimated annual revenue is currently $1.7M per year.(i)
  • Ambys Medicines's estimated revenue per employee is $77,500
  • Ambys Medicines's total funding is $187M.

Employee Data

  • Ambys Medicines has 22 Employees.(i)
  • Ambys Medicines grew their employee count by -80% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Ambys Medicines?

Ambys Medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies for people with advanced liver disease. Founded by world-renowned experts in liver disease and regenerative medicine, Ambys is pioneering the application of novel modalities including cell and gene therapy, and gain-of-function drug therapy, to meet the urgent need for treatments that have the potential to restore liver function and prevent the progression to liver failure across multiple liver diseases that are untreatable or poorly treated today. Ambys was launched in 2018 by Third Rock Ventures and Takeda Pharmaceuticals with $140M in starting capital and is headquartered in South San Francisco, Calif.

keywords:N/A

$187M

Total Funding

22

Number of Employees

$1.7M

Revenue (est)

-80%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Ambys Medicines News

2022-04-20 - Ambys Medicines Expands Leadership Team with Key ...

Ambys Medicines Expands Leadership Team with Key Appointments in Human Resources and Finance Functions. April 20, 2022 08:00 AM Eastern Daylight...

2022-04-20 - Appointments and advancements for April 20, 2022

Ambys Medicines Inc., of South San Francisco, appointed Samira Shaikhly chief human resources officer and John McKeon vice president of...

2022-04-19 - Moving the Translational Needle in Breast Cancer ...

... Vifor Pharma (I), Ambys Medicines (I), Global Blood Therapeutics (I) ... American Regent (I), Disc Medicine (I), Blue Note Therapeutics,...

2018-08-12 - Ambys Medicines Raises $60M Series A from Third Rock Ventures

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Ambys Medicines, a company founded to capitalize on advances in liver biology and regenerative medicines to develop therapies for serious liver diseases, launched today with a $60 million Series A financing funded by Third Rock Ventures and Takeda. As part ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.6M230%N/A
#2
$3.6M235%N/A
#3
$3.7M240%N/A
#4
$3.7M24-14%N/A
#5
$2.4M24N/AN/A